- Home
- VRNS vs ARQT Comparison
VRNS vs ARQT Comparison
Compare VRNS & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRNS | ARQT |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.3B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VRNS | ARQT |
|---|---|---|
| Price | $24.69 | $22.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 7 |
| Target Price | ★ $45.62 | $31.86 |
| AVG Volume (30 Days) | ★ 2.1M | 1.2M |
| Earning Date | 05-05-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | N/A | ★ N/A |
| Revenue | $270,288,000.00 | ★ $376,072,000.00 |
| Revenue This Year | $18.88 | $34.46 |
| Revenue Next Year | $17.59 | $29.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 24.35 | ★ 91.34 |
| 52 Week Low | $20.06 | $11.86 |
| 52 Week High | $63.90 | $31.77 |
Technical Indicators
Market Signals| Indicator | VRNS | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 35.75 |
| Support Level | $20.34 | $22.56 |
| Resistance Level | $28.26 | $27.26 |
| Average True Range (ATR) | 1.16 | 1.26 |
| MACD | 0.44 | -0.26 |
| Stochastic Oscillator | 88.55 | 3.25 |
Price Performance
Historical ComparisonAbout VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.